An interventional study of Pancreaticoduodenectomy with total mesopancreas excision and Standard pancreaticoduodenectomy in Pancreatic Ductal Adenocarcinoma, Pancreatic Neoplasms and Pancreatic Head Cancer, sponsored by Minia University. Not yet recruiting at 1 site in Egypt. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Minia University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Pancreatic Neoplasms by Minia University — 11 open to participants now, 11 under way, 1 of them phase 3. Pancreatic Neoplasms · Minia University.
Among the 13 studies in Pancreatic Neoplasms by Minia University, this one is the 3rd largest by planned enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2026, is one of 6 with no phase, reaches primary completion later than 6 of the 10 other live ones, and was the 12th registered.
3,897 studies on the registry are indexed under Pancreatic Neoplasms; 1,002 are open to participants now.
Browse Pancreatic Neoplasms studies →11 of the 13 studies in Pancreatic Neoplasms by Minia University are open now, in 1 country. Recruiting first, the newest first:
Minia University · Sites in Egypt
Ages 18–75
Minia University · Sites in Egypt
Ages 18–80
Minia University · Sites in Egypt
Ages 18–75
Minia University · Sites in Egypt
Ages 18–75
Minia University · Sites in Egypt
Ages 18–75
By country, each count listing its studies:
Of the 742 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2022; this study’s year is marked. 2 started in 2026.
This study's planned enrollment of 110 is above the median of 47 across 2,932 interventional studies indexed under Pancreatic Neoplasms.
Median enrollment 100 across the 10 interventional studies, 100 across the 3 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Minia University is the lead sponsor of 373 studies on the registry; 120 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
5 of the studies in Pancreatic Neoplasms by Minia University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07132541Minia UniversitySaleh's Technique for Pancreaticojejunostomy (Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate) | 2026-11-25 |
| NCT07009119Minia UniversityLaparoscopic Pancreaticoduodenectomy | 2027-02-01 |
| NCT07022015Minia UniversityPredictive Risk Factors for Pancreatic Fistula After Pancreaticoduodenectomy | 2027-03-20 |
| NCT07148830Minia UniversityMesopancreatic Excision for Pancreatic Duct Adenocarcinoma. | 2027-04-01 |
| NCT07946393Minia UniversityPreoperative CA 19-9 and the Pattern and Timing of Recurrence After Pancreatoduodenectomy (Whipple Operation) for Pancreatic Cancer | 2027-04-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 13 studies in Pancreatic Neoplasms by Minia University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Pancreatic ductal adenocarcinoma, the most common type of pancreatic cancer, is treated when it arises in the head of the pancreas and can be removed by an operation called pancreaticoduodenectomy (the Whipple operation), followed by chemotherapy. Even after this operation the cancer returns in most patients. One important reason is that microscopic cancer cells are often left at the cut edges of the removed tissue, especially at the edge facing the superior mesenteric artery, the main artery that supplies the intestine. The tissue in this area, behind the head of the pancreas, is called the mesopancreas. It contains fat, lymph vessels, lymph nodes and nerves, through which pancreatic cancer commonly spreads.
Total mesopancreas excision is a refinement of the standard operation. The surgeon removes the whole mesopancreas in one piece together with the head of the pancreas by dissecting directly along the right side of the superior mesenteric artery, in the same way that the whole fatty envelope of the rectum is removed in rectal cancer surgery. Studies that compared patients operated on with and without this technique suggest that it may leave fewer cancer cells behind and reduce the chance of the cancer returning in the operated area, without increasing complications. Those studies were not randomized, however, so it is still unknown whether the technique itself is responsible for these benefits.
In this single-center randomized controlled trial, 110 adults with removable (resectable) cancer of the head of the pancreas will be assigned by chance, during the operation and after the surgeon has confirmed that the tumor can be removed, to pancreaticoduodenectomy with total mesopancreas excision or to standard pancreaticoduodenectomy. Patients, and the doctors who examine the removed tissue and the follow-up scans, will not be told which operation was performed. The main question is whether total mesopancreas excision increases the proportion of patients in whom no cancer cells are found within 1 mm of any cut edge (an R0 resection). The trial will also compare complications, diarrhea, recovery, the number of lymph nodes removed, the chance and pattern of cancer recurrence, survival and quality of life over 2 years of follow-up.
BACKGROUND AND RATIONALE
Pancreaticoduodenectomy followed by adjuvant chemotherapy is the standard treatment for resectable pancreatic ductal adenocarcinoma (PDAC) of the pancreatic head, but most patients develop recurrence, often within 2 years (Groot et al., 2018). Microscopic involvement of the resection margins is a major cause of locoregional failure. When pancreaticoduodenectomy specimens are examined with a standardized protocol of multicolor inking and axial slicing and the 1-mm rule is applied, most PDAC resections are classified as R1 (Verbeke et al., 2006; Esposito et al., 2008; Campbell et al., 2009), and the mesopancreatic margin facing the superior mesenteric artery (SMA) is the most frequently involved site (Gaedcke et al., 2010).
The mesopancreas, introduced as a surgical concept by Gockel et al. (2007), is the retropancreatic compartment of adipose, lymphatic and neural tissue that extends from the pancreatic head and uncinate process to the SMA and the aorta. Total mesopancreas excision (TMpE), analogous to total mesorectal excision for rectal cancer, removes this compartment en bloc by a periadventitial dissection along the right side of the SMA (Adham and Singhirunnusorn, 2012; Kawabata et al., 2012; Inoue et al., 2015). Comparative series have reported higher R0 rates (Kawabata et al., 2012; Xu et al., 2017; Shyr et al., 2025) and larger lymph node yields with fewer locoregional recurrences (Xu et al., 2017; Quero et al., 2020) after TMpE than after standard pancreaticoduodenectomy. A 2024 meta-analysis of nine non-randomized studies (738 patients) found a higher R0 rate (risk ratio 1.24), fewer local recurrences (risk ratio 0.39) and no increase in overall morbidity or mortality, with a non-significant increase in postoperative diarrhea (da Silva et al., 2024). The 2026 international MESODELPHI consensus agreed on a unified definition and boundaries of the mesopancreas, favored TMpE for curative-intent surgery, and called for further investigation of its effect on survival (Leite et al., 2026). No randomized trial comparing TMpE with standard pancreaticoduodenectomy has been published (Ramia et al., 2018; da Silva et al., 2024).
At the Liver and GIT Hospital, Minia University, a single-arm cohort of 86 patients who underwent pancreaticoduodenectomy with mesopancreas excision for PDAC between 2018 and 2024 had an R0 rate of 84.9% under the Royal College of Pathologists 1-mm rule; recurrence developed in 52 patients (60.5%), with a locoregional component in 31 of them (Saleh et al., 2026). Because that study, like most of the literature, had no control group, the oncological benefit of TMpE over standard pancreaticoduodenectomy remains unproven and requires a randomized comparison.
OBJECTIVES AND HYPOTHESIS
The primary objective is to determine whether pancreaticoduodenectomy with TMpE increases the R0 resection rate, defined as tumor clearance of 1 mm or more at all resection margins, compared with standard pancreaticoduodenectomy in patients with resectable PDAC of the pancreatic head. The hypothesis is that TMpE increases the R0 rate from 60% to 85%.
The secondary objectives are to compare SMA-margin involvement, lymph node yield, locoregional and distant recurrence, disease-free and overall survival, postoperative morbidity (including pancreatic fistula, hemorrhage, delayed gastric emptying, chyle leak and diarrhea), recovery, delivery of adjuvant chemotherapy and quality of life between the two operations.
STUDY DESIGN AND SETTING
This is a single-center, randomized, parallel-group (1:1) superiority trial with masked participants and masked outcome assessors, conducted at the Department of Surgery, Liver and GIT Hospital, Faculty of Medicine, Minia University, Minya, Egypt. The protocol follows the SPIRIT 2025 statement, and the trial will be reported according to CONSORT 2025 and its extension for non-pharmacologic treatments.
SCREENING AND STAGING
Consecutive adults referred with a mass in the pancreatic head or uncinate process are screened. Staging consists of pancreatic-protocol contrast-enhanced multidetector CT of the chest, abdomen and pelvis within 4 weeks before surgery, serum CA19-9, and endoscopic ultrasound with fine-needle aspiration or biopsy when the multidisciplinary tumor board requires a tissue diagnosis. Resectability is defined by NCCN criteria (Tempero et al., 2021). Preoperative biliary drainage is reserved for cholangitis, severe jaundice or an expected delay to surgery, according to unit policy.
RANDOMIZATION AND ALLOCATION CONCEALMENT
A statistician not involved in recruitment or treatment generates the allocation sequence by computer, using permuted blocks of variable size (4 and 6) stratified by venous contact on preoperative CT (no contact versus contact of 180 degrees or less with the superior mesenteric vein or portal vein). Allocations are kept in sequentially numbered, opaque, sealed envelopes outside the operating room. Written informed consent is obtained before surgery. Randomization takes place during the operation, after exploration has excluded peritoneal and liver metastases and confirmed local resectability, when the circulating nurse opens the next envelope of the relevant stratum. Patients found to be unresectable before randomization are not randomized and are recorded as screening failures.
MASKING
The operating surgeons cannot be masked. Participants are not told their allocation until follow-up is complete. Specimens are sent to pathology labeled with the trial number only, with a request form that does not state the allocation, and a second pathologist re-measures the margin distances on the slides. Postoperative complications are graded, and follow-up imaging is reviewed for recurrence, by investigators who did not take part in the operation and are masked to allocation. The statistician analyzes a dataset in which the arms are coded.
INTERVENTIONS
Both arms: All operations are open pancreaticoduodenectomies, pylorus-preserving or pylorus-resecting according to tumor extent, performed by senior hepatopancreatobiliary surgeons of the unit who have used TMpE since 2018 and perform more than 50 pancreaticoduodenectomies per year. Both arms receive the ISGPS standard lymphadenectomy (stations 5, 6, 8a, 12b1, 12b2, 12c, 13a, 13b, 14a, 14b, 17a and 17b; Tol et al., 2014). Portal or superior mesenteric vein resection is performed in either arm when needed for tumor clearance. Reconstruction, drain policy, antibiotic and thromboembolic prophylaxis, and the enhanced-recovery pathway are the same in both arms.
Experimental arm (TMpE): An artery-first approach exposes the SMA at its origin to confirm the absence of arterial involvement. The mesopancreas is excised en bloc with the pancreatic head and uncinate process within these boundaries: the superior mesenteric vein/portal vein axis and the right semicircumference of the SMA anteriorly and medially; the adventitia of the inferior vena cava, left renal vein and aorta posteriorly; the origins of the celiac trunk and SMA superiorly; and the lower border of the uncinate process and the first jejunal vessels inferiorly. The SMA is dissected in the periadventitial plane over its right hemicircumference (about 180 degrees) from the aortic origin to the origin of the first jejunal artery. The inferior pancreaticoduodenal artery, or its common trunk with the first jejunal artery, is ligated at its origin, and the right-sided SMA nerve plexus is removed with the specimen while the left-sided plexus is preserved. Extension of the periarterial clearance up to 270 degrees is allowed only when periarterial tumor extension is suspected during surgery and is recorded as a protocol variation.
Control arm (standard pancreaticoduodenectomy): A conventional vein-first approach is used (Kocher maneuver, tunneling behind the pancreatic neck and transection of the neck). The uncinate process is divided from the superior mesenteric vein and from the right side of the SMA, ligating the pancreaticoduodenal branches close to the pancreas. The SMA is not dissected in the periadventitial plane, its nerve plexus is preserved, and the retropancreatic tissue is not excised as an en bloc compartment; station 14a and 14b nodes are removed superficial to the nerve plexus.
Surgical quality assurance: Standardized photographs of the operative field after resection and of the specimen are taken in every case and reviewed by an independent senior surgeon to confirm that the allocated technique was performed. Crossovers and protocol deviations are documented.
PATHOLOGY PROTOCOL
The surgeon marks the SMA margin and the superior mesenteric vein groove with sutures. Specimens are examined with a standardized protocol based on multicolor inking of the margins and surfaces, axial slicing perpendicular to the duodenal axis at 3 to 5 mm intervals, and extensive sampling (Verbeke et al., 2006). The minimum distance between tumor and each margin is measured microscopically. R0 is defined as clearance of 1 mm or more at all resection margins (SMA, superior mesenteric vein/portal vein groove, posterior, pancreatic neck, bile duct, and proximal and distal enteric margins). R1 is defined as tumor less than 1 mm from any resection margin and is subdivided into direct (0 mm) and indirect (more than 0 mm and less than 1 mm) involvement. Involvement of the anterior pancreatic surface is recorded separately. Lymph nodes are reported by station, staging follows the 8th edition of the AJCC/UICC TNM classification, and perineural, lymphovascular and retropancreatic soft-tissue invasion are recorded.
POSTOPERATIVE CARE, ADJUVANT THERAPY AND FOLLOW-UP
Complications are recorded prospectively for 90 days and graded by the Clavien-Dindo classification (Dindo et al., 2004) and the Comprehensive Complication Index (Slankamenac et al., 2013). Postoperative pancreatic fistula, delayed gastric emptying, post-pancreatectomy hemorrhage and chyle leak follow the ISGPS definitions (Bassi et al., 2017; Wente et al., 2007a; Wente et al., 2007b; Besselink et al., 2017). Diarrhea is graded by the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 at every visit for 6 months. Adjuvant chemotherapy is decided by the clinical oncology team, which is masked to allocation: modified FOLFIRINOX for fit patients or gemcitabine plus capecitabine, planned for 6 months and started within 12 weeks of surgery (Neoptolemos et al., 2017; Conroy et al., 2018). Follow-up visits occur at 1, 3, 6, 9, 12, 18 and 24 months, with clinical examination and serum CA19-9 at each visit. Contrast-enhanced CT of the chest, abdomen and pelvis is performed at 3, 6, 9, 12, 18 and 24 months and whenever recurrence is suspected, with MRI, PET-CT or biopsy when needed. Recurrence is classified as locoregional (pancreatic or mesopancreatic bed around the SMA, celiac axis and superior mesenteric vein/portal vein, anastomoses, or regional lymph nodes), distant (liver, lungs, peritoneum, bone, non-regional lymph nodes or other organs) or combined, and is adjudicated by a radiologist masked to allocation. Quality of life is assessed with the EORTC QLQ-C30 at baseline and at 3, 6 and 12 months.
SAMPLE SIZE
The sample size is based on the primary outcome. The expected R0 rate is 60% after standard pancreaticoduodenectomy (Kawabata et al., 2012) and 85% after TMpE, based on the institutional series in which a comparable protocol (axial slicing, margin inking and the 1-mm rule) gave an R0 rate of 84.9% (Saleh et al., 2026). A difference of this size is consistent with the higher R0 rates reported in comparative series and with the mesopancreatic margin being the most common site of R1 resection (Gaedcke et al., 2010; da Silva et al., 2024). Detecting it with 80% power and a two-sided alpha of 0.05 (chi-square test) requires 49 participants per arm. Allowing 10% for post-randomization exclusions (final histology other than PDAC, or withdrawal), 55 participants per arm will be randomized (110 in total). Recruitment is planned over 12 months, from December 2026 to November 2027.
STATISTICAL ANALYSIS
The primary analysis follows a modified intention-to-treat approach: all randomized participants with histologically confirmed PDAC, analyzed in the arm to which they were allocated. A per-protocol analysis excluding crossovers and major protocol deviations is a sensitivity analysis. R0 rates are compared with the chi-square test and reported as the absolute risk difference and risk ratio with 95% confidence intervals; logistic regression adjusted for the stratification factor is a supportive analysis. Other categorical outcomes are compared with the chi-square or Fisher exact test, and continuous outcomes with the t-test or Mann-Whitney U test. Disease-free and overall survival are estimated by the Kaplan-Meier method, compared with the log-rank test and modeled with Cox regression adjusted for the stratification factor. Locoregional and distant recurrence are analyzed as cumulative incidence with death as a competing event (Gray test and Fine-Gray model). Quality-of-life scores are analyzed with linear mixed models. Prespecified subgroup analyses of the primary outcome are by venous contact and by tumor size on CT (2 cm or less versus more than 2 cm). Missing secondary outcome data are handled by multiple imputation if more than 5% are missing. All tests are two-sided at a significance level of 0.05; secondary outcomes are not adjusted for multiplicity and are interpreted as exploratory. Analyses are performed with SPSS version 26 and R.
DATA MANAGEMENT AND MONITORING
Data are recorded on standardized case report forms and entered into a password-protected database with coded identifiers; the primary outcome is verified against source documents for every participant. An independent data and safety monitoring board (a hepatopancreatobiliary surgeon, a clinical oncologist and a biostatistician, none involved in the trial) reviews unmasked safety data, including 90-day mortality, complications of Clavien-Dindo grade IIIa or higher, grade B or C pancreatic fistula and hemorrhage, and diarrhea of CTCAE grade 3 or higher, after 30 and after 55 participants have completed 90 days of follow-up, and may recommend modification or early termination for safety. No interim efficacy analysis is planned. Serious adverse events are reported to the Institutional Review Board according to its requirements.
ETHICS AND DISSEMINATION
The protocol was approved by the Institutional Review Board, Faculty of Medicine, Minia University (MUFMIRB approval number 1702:09/2025, 15 September 2025). The trial is conducted in accordance with the Declaration of Helsinki, ICH Good Clinical Practice and Egyptian Law No. 214 of 2020 on clinical medical research. All participants give written informed consent before surgery, including consent to randomization during the operation, and may withdraw at any time without any effect on their care. Results will be published in a peer-reviewed journal and reported on ClinicalTrials.gov regardless of the findings.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Open pancreaticoduodenectomy using an artery-first approach with en bloc total mesopancreas excision: periadventitial dissection of the right hemicircumference (about 180 degrees) of the superior mesenteric artery from its aortic origin to the first jejunal artery, ligation of the inferior pancreaticoduodenal artery at its origin, and removal of the retropancreatic fat, lymphatic and neural tissue (including the right-sided superior mesenteric artery nerve plexus) down to the inferior vena cava, left renal vein and aorta, plus ISGPS standard lymphadenectomy. Reconstruction and perioperative care are identical to the control arm.
Procedure: Pancreaticoduodenectomy with total mesopancreas excision
Open pancreaticoduodenectomy using the conventional vein-first approach, with division of the uncinate process from the superior mesenteric vein and the right side of the superior mesenteric artery close to the pancreas, without periadventitial dissection of the artery or resection of its nerve plexus, plus ISGPS standard lymphadenectomy. Reconstruction and perioperative care are identical to the experimental arm.
Procedure: Standard pancreaticoduodenectomy
Open pancreaticoduodenectomy (pylorus-preserving or pylorus-resecting) with an artery-first approach. The mesopancreas is excised en bloc with the pancreatic head and uncinate process within these boundaries: the superior mesenteric vein/portal vein axis and the right semicircumference of the superior mesenteric artery anteriorly and medially; the adventitia of the inferior vena cava, left renal vein and aorta posteriorly; the origins of the celiac trunk and superior mesenteric artery superiorly; and the lower border of the uncinate process inferiorly. The artery is cleared in the periadventitial plane over about 180 degrees on its right side from the aorta to the first jejunal artery, with ligation of the inferior pancreaticoduodenal artery at its origin; the left-sided nerve plexus is preserved. Extension up to 270 degrees is allowed only for suspected periarterial tumor extension. ISGPS standard lymphadenectomy.
Also known as: Total mesopancreas excision (TMpE), Mesopancreas excision, Systematic mesopancreas dissection
Open pancreaticoduodenectomy (pylorus-preserving or pylorus-resecting) using the conventional vein-first approach: Kocher maneuver, tunneling behind the pancreatic neck and neck transection, then division of the uncinate process from the superior mesenteric vein and from the right side of the superior mesenteric artery, with ligation of the pancreaticoduodenal branches close to the pancreas. The artery is not dissected in the periadventitial plane, its nerve plexus is preserved, and the retropancreatic tissue is not excised as an en bloc compartment. ISGPS standard lymphadenectomy (stations 5, 6, 8a, 12b1, 12b2, 12c, 13a, 13b, 14a, 14b, 17a and 17b), with station 14a and 14b nodes removed superficial to the nerve plexus.
Also known as: Whipple procedure, Conventional pancreaticoduodenectomy
R0 Resection Rate (Tumor Clearance of 1 mm or More at All Resection Margins)
Proportion of participants with an R0 resection on final histopathology. R0 is defined as a minimum microscopic distance of 1 mm or more between tumor and every resection margin (superior mesenteric artery margin, superior mesenteric vein/portal vein groove margin, posterior margin, pancreatic neck transection margin, bile duct margin, and proximal and distal enteric margins), assessed with a standardized protocol of multicolor inking and axial slicing. Pathologists are masked to allocation, and a second pathologist re-measures margin distances on the slides. Analyzed in randomized participants with histologically confirmed pancreatic ductal adenocarcinoma.
Time frame: Final histopathology report, within 3 weeks after surgery
Superior Mesenteric Artery (Mesopancreatic) Margin Involvement
Proportion of participants with tumor less than 1 mm from the inked superior mesenteric artery (mesopancreatic) margin on final histopathology.
Time frame: Final histopathology report, within 3 weeks after surgery
R1 Direct Resection Rate (Tumor at a Resection Margin)
Proportion of participants with tumor cells at the inked surface (0 mm) of any resection margin on final histopathology.
Time frame: Final histopathology report, within 3 weeks after surgery
Number of Lymph Nodes Examined
Total number of lymph nodes retrieved from the resection specimen and examined histologically.
Time frame: Final histopathology report, within 3 weeks after surgery
Locoregional Recurrence
Cumulative incidence of locoregional recurrence (pancreatic or mesopancreatic bed around the superior mesenteric artery, celiac axis and superior mesenteric vein/portal vein, surgical anastomoses, or regional lymph nodes), isolated or combined with distant recurrence, diagnosed on contrast-enhanced CT with MRI, PET-CT or biopsy when required and adjudicated by a radiologist masked to allocation. Death without recurrence is treated as a competing event.
Time frame: From surgery up to 24 months
Distant Recurrence
Cumulative incidence of recurrence in the liver, lungs, peritoneum, bone, non-regional lymph nodes or other distant sites, diagnosed and adjudicated as for locoregional recurrence. Death without recurrence is treated as a competing event.
Time frame: From surgery up to 24 months
Disease-Free Survival
Time from surgery to first recurrence at any site or death from any cause, estimated by the Kaplan-Meier method and reported as the 2-year disease-free survival rate.
Time frame: From surgery up to 24 months
Overall Survival
Time from surgery to death from any cause, estimated by the Kaplan-Meier method and reported as the 2-year overall survival rate.
Time frame: From surgery up to 24 months
Operative Time
Time from skin incision to completion of skin closure, in minutes.
Time frame: During surgery
Intraoperative Blood Loss
Estimated blood loss in milliliters, measured from suction volume and weighed swabs.
Time frame: During surgery
Overall Postoperative Morbidity
Proportion of participants with at least one postoperative complication of any grade according to the Clavien-Dindo classification.
Time frame: Within 90 days after surgery
Major Postoperative Morbidity (Clavien-Dindo Grade IIIa or Higher)
Proportion of participants with at least one complication of Clavien-Dindo grade IIIa or higher.
Time frame: Within 90 days after surgery
Comprehensive Complication Index
Cumulative burden of all postoperative complications on a continuous scale from 0 (no complication) to 100 (death).
Time frame: Within 90 days after surgery
Clinically Relevant Postoperative Pancreatic Fistula (ISGPS Grade B or C)
Proportion of participants with grade B or C postoperative pancreatic fistula according to the 2016 International Study Group of Pancreatic Surgery (ISGPS) definition.
Time frame: Within 90 days after surgery
Post-Pancreatectomy Hemorrhage (ISGPS Grade B or C)
Proportion of participants with grade B or C post-pancreatectomy hemorrhage according to the ISGPS definition.
Time frame: Within 90 days after surgery
Delayed Gastric Emptying (ISGPS Grade B or C)
Proportion of participants with grade B or C delayed gastric emptying according to the ISGPS definition.
Time frame: Within 90 days after surgery
Chyle Leak (ISGPS Grade B or C)
Proportion of participants with grade B or C chyle leak according to the ISGPS definition.
Time frame: Within 90 days after surgery
Clinically Significant Postoperative Diarrhea (CTCAE Grade 2 or Higher)
Proportion of participants with diarrhea of grade 2 or higher according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, assessed at every visit.
Time frame: Within 6 months after surgery
Unplanned Reoperation
Proportion of participants who require an unplanned return to the operating room.
Time frame: Within 90 days after surgery
Length of Postoperative Hospital Stay
Number of days from surgery to hospital discharge.
Time frame: From surgery to discharge, up to 90 days
Hospital Readmission
Proportion of participants readmitted to hospital after discharge.
Time frame: Within 90 days after surgery
90-Day Mortality
Proportion of participants who die from any cause within 90 days after surgery.
Time frame: Within 90 days after surgery
Initiation of Adjuvant Chemotherapy Within 12 Weeks
Proportion of participants who start adjuvant chemotherapy within 12 weeks after surgery.
Time frame: Within 12 weeks after surgery
Health-Related Quality of Life (EORTC QLQ-C30 Global Health Status)
Global health status/quality of life score of the European Organisation for Research and Treatment of Cancer QLQ-C30 questionnaire, from 0 to 100; higher scores indicate better quality of life.
Time frame: Baseline and 3, 6 and 12 months after surgery
Minimum Tumor Clearance at the Superior Mesenteric Artery Margin
Microscopic distance, in millimeters, between the tumor and the inked superior mesenteric artery margin.
Time frame: Final histopathology report, within 3 weeks after surgery
Lymph Node Ratio
Number of metastatic lymph nodes divided by the number of lymph nodes examined.
Time frame: Final histopathology report, within 3 weeks after surgery
Metastasis in Lymph Nodes Along the Superior Mesenteric Artery (Station 14)
Proportion of participants with at least one metastatic station 14 lymph node.
Time frame: Final histopathology report, within 3 weeks after surgery
Tumor Invasion of the Retropancreatic Soft Tissue or Nerve Plexus
Proportion of participants with histological tumor invasion (direct, perineural or lymphovascular) of the resected retropancreatic soft tissue or nerve plexus.
Time frame: Final histopathology report, within 3 weeks after surgery
Anterior Pancreatic Surface Involvement
Proportion of participants with tumor at the inked anterior surface of the pancreas (0 mm).
Time frame: Final histopathology report, within 3 weeks after surgery
Pattern of First Recurrence
Distribution of first recurrence as isolated locoregional, isolated distant, or combined locoregional and distant recurrence.
Time frame: From surgery up to 24 months
Plan to share: No
Start is estimated for Nov 2026; primary completion for Dec 2027, 13 months later.
Of 403 non-industry interventional studies with no phase under Pancreatic Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 75. This study's planned 13 months is below that.
Counting every sponsor, half of 430 studies reached it within 44 months; a quarter within 26 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.